Prediabetes: the years before the diagnosis
Last reviewed November 17, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.
Prediabetes means blood sugar is above normal but below the diabetes threshold. More than one in three United States adults has it, and most do not know.
It is the single best opportunity in the whole story, because this is the stage at which the trajectory can still be changed cheaply and without medicines.
Related pages: Type 2 diabetes
The bottom line
- Prediabetes is defined as an A1C of 5.7 to 6.4 percent, a fasting glucose of 100 to 125 mg/dL, or a 2-hour test of 140 to 199 mg/dL.
- Insulin resistance and beta-cell decline are already under way at this stage.
- Structured lifestyle programs cut progression to diabetes by about 58 percent over three years.
- Metformin also reduces progression, by about 31 percent, and more in younger people and those with higher body weight.
- Not everyone with prediabetes progresses.
- How many people with prediabetes revert to normal on their own, and why.
- Whether treating prediabetes reduces heart attacks and strokes, as opposed to delaying a diagnosis.
- Whether the A1C cut-off of 5.7 is the right place to draw the line.
The story, step by step
What the evidence labels mean
What counts as prediabetes
What happens
Three tests, three ranges.
What the research shows
- A1C of 5.7 to 6.4 percent. Below 5.7 is normal; 6.5 and above is diabetes.
- Fasting plasma glucose of 100 to 125 mg/dL, after at least eight hours without food. Below 100 is normal; 126 and above is diabetes.
- Two-hour value of 140 to 199 mg/dL on an oral glucose tolerance test. Below 140 is normal; 200 and above is diabetes.
- The three tests do not always agree, and a person can be prediabetic by one and normal by another.
- The oral glucose tolerance test is the most sensitive of the three and the least used, because it takes two hours.
- Within the prediabetes band, the higher the number, the higher the yearly risk of progressing.
Why it matters
Prediabetes is not a mild version of diabetes. It is a measured range on the way there, with a known and modifiable rate of travel.
What's still uncertain
- Whether the fasting threshold should be 100 or 110, which differs between guidelines.
- How well A1C performs in people with anaemia, kidney disease or certain haemoglobin variants.
Read more
- NIDDK: Insulin resistance and prediabetesGovernment
- MedlinePlus: PrediabetesGovernment
- American Diabetes Association: standards of care resourcesNonprofit
Next: The odds
How often it progresses
What happens
Common, but not inevitable.
What the research shows
- Without intervention, roughly 5 to 10 percent of people with prediabetes develop diabetes each year.
- Over a lifetime a large share progress, but a meaningful minority return to normal blood sugar without any treatment.
- Risk is highest for those at the top of the range, with a strong family history, with substantial abdominal weight, or with a history of gestational diabetes.
- Progression is not linear. Blood sugar can drift up and down for years.
- Complications usually associated with diabetes, particularly nerve damage and early eye changes, are occasionally found at the prediabetes stage.
- Heart and blood vessel risk is already modestly raised in prediabetes, before the diabetes threshold is crossed.
Why it matters
A prediabetes result is information about direction of travel, not a verdict. It is worth acting on and not worth panicking about.
What's still uncertain
- Why some people revert spontaneously.
- Whether earlier treatment prevents cardiovascular events or just relabels them.
Read more
- CDC: National Diabetes Prevention ProgramGovernment
- USPSTF: Screening for prediabetes and type 2 diabetesGovernment
- NIDDK: Insulin resistance and prediabetesGovernment
Next: What works
The Diabetes Prevention Program
What happens
The trial that defined the advice.
What the research shows
- The Diabetes Prevention Program enrolled over 3,000 adults with prediabetes and compared a structured lifestyle program, metformin and placebo.
- The lifestyle group aimed for 7 percent weight loss and 150 minutes of activity a week, supported by a coach and regular sessions.
- Lifestyle reduced progression to diabetes by 58 percent over about three years; metformin reduced it by 31 percent.
- In adults over 60 the lifestyle effect was larger, around 71 percent. Metformin worked best in younger participants and those with higher body weight.
- Benefits persisted on long-term follow-up, though the gap narrowed as the comparison groups also developed diabetes.
- This trial is why the CDC's National Diabetes Prevention Program exists, and why it is built around a coach and a year-long curriculum rather than a leaflet.
Why it matters
The intervention that worked was a structured, supported program with modest goals, not an extreme diet. The numbers people are asked to hit are the numbers that were actually tested.
What's still uncertain
- Whether newer weight-loss medicines prevent diabetes as durably as lifestyle change.
- How well the effect holds in real-world programs compared with a trial setting.
Read more
- NIH: Diabetes Prevention Program outcomesGovernment
- CDC: National Diabetes Prevention ProgramGovernment
- NIDDK: Insulin resistance and prediabetesGovernment
Next: Getting tested
Who should be screened
What happens
More people than are currently offered it.
What the research shows
- Screening is recommended for all adults from age 35 to 70 who are overweight or obese, and repeated at least every three years if normal.
- Earlier and more frequent screening applies with a first-degree relative with diabetes, a history of gestational diabetes, polycystic ovary syndrome, high blood pressure, abnormal lipids or heart disease.
- A single A1C or fasting glucose is enough to start. No special preparation is needed for A1C.
- An abnormal result should be confirmed, usually with a repeat test, before any label is applied.
- People with prediabetes should be rechecked yearly.
- Screening is free of cost-sharing under most United States insurance when it meets the recommended criteria.
Why it matters
The test is cheap, the window is long and the intervention works. Few things in preventive medicine line up this well.
What's still uncertain
- The best screening interval for people at low risk.
- Whether screening below age 35 is worthwhile given rising rates in younger adults.